The research began with a question that has lingered in the muscle biology literature for years. Calcium dysregulation is a well-documented feature of diseased and aging muscle. Patients with systemic hypercalcemia, defined by serum calcium exceeding 3.0 millimolar, frequently complain of fatigue and proximal muscle weakness. Duchenne muscular dystrophy drives chronic cytosolic calcium overload through loss of the structural protein dystrophin. Aging muscle, meanwhile, shows increased resting intracellular calcium, leaky ryanodine receptors, and inefficient calcium reuptake by SERCA pumps. Yet most research had focused on how calcium controls contraction in mature fibers, leaving the impact on regenerating muscle largely unexplored.

To connect those dots, the team, led by Kee K. Kim of Chungnam National University, first turned to human data. Analyzing transcriptomes from 679 individuals in the GTEx v8 dataset, they compared gastrocnemius muscle from people aged 50 and older with samples from those under 40. Gene set enrichment analysis revealed that aged muscle showed coordinated activation of calcium signaling pathways and muscle cell proliferation programs, alongside upregulation of the quiescence regulator SPRY1, the early myogenic factor PAX3, and the proliferation marker CCND1. Crucially, the signature appeared in both men and women, suggesting that a proliferative bias tied to calcium signaling is a general feature of aging muscle rather than a sex-specific phenomenon.

The researchers then moved into the laboratory to test whether calcium excess directly alters myoblast behavior. When C2C12 mouse myoblasts and primary myoblasts isolated from hindlimb muscle were exposed to elevated calcium chloride under normal growth conditions, nothing dramatic happened. But when the same cells were pushed to differentiate while bathed in 3 or 6 millimolar calcium chloride, a striking picture emerged: total cell numbers rose significantly, the proliferative marker PAX7 climbed at both the protein and mRNA levels, and the cells failed to exit the cell cycle. Calcium imaging with the Fluo-4 AM indicator confirmed that intracellular calcium remained persistently elevated throughout the differentiation window, rising in a dose-dependent manner in primary myoblasts.

That persistent proliferative state came at a direct cost to myogenesis. Myotube formation declined dose-dependently in calcium-exposed C2C12 cultures, and levels of the myogenic markers MYH3 and myogenin dropped alongside their messenger RNAs. Primary mouse myoblasts showed the same defects, and, importantly, the phenomenon crossed the species line: human embryonic stem cell-derived myoblasts differentiated for two weeks in 3 millimolar calcium chloride formed fewer myotubes and produced less total myosin heavy chain. Notably, prolonged exposure to lower concentrations sufficed to impair differentiation, indicating that the duration of calcium elevation, rather than its absolute peak, is the critical determinant of pathology.

RNA sequencing of calcium-exposed primary myoblasts identified 2,776 differentially expressed genes and revealed the underlying transcriptional logic. Genes upregulated by calcium exposure were enriched for cell division and chromosome segregation, while downregulated genes clustered around muscle contraction and sarcomere organization. Gene set enrichment analysis flagged activation of the calcium-dependent NFAT pathway. Mechanistic experiments followed: NFATc1, tagged with green fluorescent protein, translocated into the nucleus of calcium-exposed myoblasts; the NFAT target gene Ccnd1, encoding cyclin D1, was upregulated; and chromatin immunoprecipitation showed that NFATc1 binding to the Ccnd1 promoter was significantly enhanced under calcium excess. In short, calcium was hijacking a pathway that normally helps orchestrate differentiation and repurposing it to keep the cell-cycle engine running.

To confirm the mechanism in living animals, the team used two complementary models. The first was the ovariectomized mouse, in which estrogen deficiency destabilizes calcium handling by hyperphosphorylating the ryanodine receptor 1, provoking spontaneous calcium release from the sarcoplasmic reticulum. These mice lost bone density, performed worse on treadmill endurance tests, and developed gastrocnemius atrophy. Their muscle transcriptomes mirrored the in vitro signature: enrichment of calcium signaling and proliferation programs, downregulation of developing and mature myosin heavy chain genes, upregulation of Pax7 and MyoD, shrunken myofiber cross-sectional areas, and clear nuclear translocation of NFATc1. The second model was human calcific tendinitis. In supraspinatus muscle samples taken from patients during calcific deposit removal, tissue adjacent to the calcium deposits showed downregulation of SPRY1, PAX3, and MYH3 together with upregulation of CCND1 compared with remote regions, demonstrating that even localized calcium overload in human tissue produces the same proliferative, anti-myogenic fingerprint.

The most translational part of the study came from pharmacological rescue. Using VIVIT, a selective peptide inhibitor of NFAT, the researchers blocked calcium-induced nuclear accumulation of NFATc1 in both C2C12 cells and primary myoblasts. VIVIT restored MYH3 expression and reversed the myotube formation defect under calcium overload. A complementary experiment using caffeine to induce sarcoplasmic reticulum calcium leak recapitulated the suppression of myoblast fusion, and VIVIT rescued that too, confirming the effect arises from intracellular calcium dysregulation rather than nonspecific stress. In vivo, the team injured tibialis anterior muscles with barium chloride, which triggers calcium-dependent proteolysis and robust regeneration, and injected VIVIT locally on days 0 and 2. Treated muscles showed improved regenerative morphology, larger myofiber cross-sectional areas, and a dramatic reduction in the proportion of immature myogenin-positive fibers, all without measurable changes in inflammatory markers such as Il6, Tnfa, and Inos.

One conceptual takeaway is that NFAT plays a duration-dependent dual role in muscle. Transient calcium-dependent NFAT activation has classically been viewed as a positive regulator of myogenesis, supporting fiber-type specification and hypertrophy. The new data show that when calcium elevation persists, the same pathway flips into an anti-myogenic mode, sustaining cyclin D1 expression and preventing the cell-cycle exit that myoblasts must undergo to fuse into contractile fibers. The authors also suggest this framework may help explain osteosarcopenia, the poorly understood co-occurrence of osteoporosis and muscle loss, since both tissues depend on well-regulated calcium handling, although they caution that this connection remains inferential and requires direct testing.

Limitations remain, and the researchers are candid about them. The therapeutic benefit of VIVIT was demonstrated in an acute injury model, not in the chronic ovariectomy setting, because repeated intramuscular injections over a six-week protocol would introduce local tissue damage and inflammation that could confound the results. Future work with long-term pharmacological approaches or genetic models will be needed to validate NFAT as a drug target for chronic calcium-associated myopathies. Still, by tracing a single molecular thread from aged human muscle through mouse myoblasts, ovariectomized mice, calcific tendinitis patients, and a rescued injury model, the study establishes chronic calcium-NFAT signaling as a credible mechanism linking calcium dysregulation to failed muscle repair, and it offers a concrete starting point for therapies aimed at restoring the regenerative capacity of weakened muscle.

Subject of Research: Mechanism by which pathological calcium overload impairs skeletal muscle regeneration through sustained NFAT-dependent proliferative signaling

Article Title: Pathological calcium overload impairs skeletal muscle regeneration through sustained NFAT-dependent proliferative signaling

Article References: Lee, S., Cho, N., Jo, S., Ji, J.-H., Kim, J. O., Park, C., Choi, S., Kim, E.-M., & Kim, K. K. (2026). Pathological calcium overload impairs skeletal muscle regeneration through sustained NFAT-dependent proliferative signaling. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01856-3

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01856-3

Keywords: skeletal muscle, muscle regeneration, calcium signaling, NFATc1, myogenesis, satellite cells, cyclin D1, sarcopenia, calcific tendinitis, VIVIT, aging muscle, ovariectomy

Premature ovarian insufficiency, or POI, affects a meaningful fraction of women of reproductive age and carries consequences that extend far beyond infertility. Women with the condition face elevated risks of osteoporosis, cardiovascular disease, and the psychological burden of an unexpectedly early menopause. A 2023 systematic review and meta-analysis cited in the study estimated the global prevalence of the disorder, and clinicians have struggled for years with the fact that most cases have no identifiable cause. Genetic abnormalities, chemotherapy, and autoimmune damage account for only a subset of diagnoses, leaving a large majority classified as idiopathic. That gap in understanding has pushed investigators toward environmental suspects, and among them one chemical has drawn particular attention: bisphenol A.

Bisphenol A, commonly abbreviated as BPA, is an industrial compound used in the manufacture of polycarbonate plastics and epoxy resins, which find their way into food containers, water bottles, thermal receipt paper, and countless everyday products. Because BPA can mimic estrogen in the body, it belongs to a class of substances called endocrine-disrupting chemicals, and it is so widespread in modern environments that measurable traces appear in the urine of most people tested. Prior research, including animal work showing that BPA can trigger premature activation of primordial follicles in mouse ovaries through the PTEN signaling pathway, has already linked the chemical to ovarian damage. Epidemiological studies have also associated urinary BPA concentrations with reduced antral follicle counts among women attending infertility clinics. What remained unclear was the precise molecular mechanism by which BPA might impair the ovarian cells responsible for supporting follicle development.

The research team, led by Erqiu Du and Wei Xu of Taizhou Central Hospital in Zhejiang Province, China, together with co-first author Jin Pan of Shaoxing University, approached this question from the angle of gene regulation. Their focus fell on microRNAs, tiny noncoding RNA fragments, typically around twenty-two nucleotides long, that act as post-transcriptional regulators. Rather than encoding proteins, these small molecules bind to complementary sequences in messenger RNAs and either block their translation into protein or mark them for degradation. A single microRNA can tune the expression of dozens of target genes, which makes them powerful control points in cellular processes, and previous studies have already identified altered microRNA profiles in the blood plasma of women with premature ovarian failure, including changes in molecules such as miR-23a and miR-22-3p.

To dissect the relationship among BPA, microRNAs, and cell cycle control, the investigators used cell culture and transfection techniques in the laboratory, exposing ovarian granulosa cells to BPA and measuring the consequences for cell proliferation. Granulosa cells are the somatic cells that surround developing oocytes within follicles, and their healthy proliferation is essential for follicular growth, ovulation, and the production of hormones that sustain the menstrual cycle. Because these cells must divide in a tightly coordinated fashion as follicles mature, any interference with their cell cycle machinery can ripple outward into compromised ovarian function. The team employed quantitative real-time polymerase chain reaction to quantify microRNA expression levels and Western blotting to assess protein abundance, providing complementary molecular readouts of what BPA was doing inside the cells.

The results were consistent and revealing. BPA exposure significantly inhibited the proliferation of the granulosa cells, and that growth arrest was closely associated with two parallel molecular changes: an upregulation of specific microRNAs, prominently including miR-26a-3p, and a downregulation of the CCND1 protein. Cyclin D1 is a central figure in the G1 phase of the cell cycle, the interval during which a cell grows and prepares to duplicate its DNA. By partnering with cyclin-dependent kinases, Cyclin D1 helps push cells through the restriction point that commits them to division. When Cyclin D1 levels fall, cells stall before DNA replication, and tissue renewal slows. The correspondence between rising miR-26a-3p and falling CCND1 suggested to the researchers a direct regulatory relationship, consistent with the known capacity of microRNAs to suppress specific target transcripts.

Perhaps the most compelling evidence came from the team’s manipulation experiments. When the researchers artificially increased the levels of the identified microRNAs through transfection, the overexpression partially reversed the BPA-induced changes in CCND1 expression, supporting the idea that the microRNA sits upstream of the cell cycle protein in the pathway affected by BPA. In other words, the data fit a model in which BPA exposure raises miR-26a-3p abundance, which in turn suppresses CCND1, thereby throttling granulosa cell proliferation. While the word partially is important, since it indicates that other pathways likely operate alongside this one, the demonstration that a single microRNA can modulate the response to BPA offers a concrete mechanistic handle on what has been a murky problem.

The significance of this work lies in how it connects three previously separate threads: environmental exposure, small RNA regulation, and cell cycle control in the ovary. For years, studies of POI have documented associations between endocrine-disrupting chemicals and reproductive harm, and separate bodies of literature have catalogued microRNA alterations in ovarian disease. By placing miR-26a-3p and CCND1 in a single causal chain, the study supplies a plausible molecular bridge between the two. It also aligns with a broader shift in reproductive biology, in which noncoding RNAs are increasingly recognized as biomarkers and therapeutic targets in female infertility, a trend reflected in recent reviews of microRNAs in primary ovarian insufficiency and related conditions such as diminished ovarian reserve and poor ovarian response.

As with all cell culture studies, important caveats apply. The experiments were conducted entirely in vitro, without human participants, clinical trials, or animal studies, and the researchers note that ethics approval and participant consent were not applicable for that reason. Laboratory cell lines, even ones such as the well-characterized steroidogenic granulosa-like KGN line that expresses functional follicle-stimulating hormone receptors, cannot fully reproduce the complex hormonal and structural environment of a living ovary. Whether the BPA concentrations used in culture correspond meaningfully to real-world human exposure levels, and whether the same microRNA-protein axis operates in granulosa cells within intact follicles, will require further investigation in animal models and, eventually, human tissue studies. The authors themselves emphasize that future research should further elucidate the specific roles of these microRNAs and CCND1 in ovarian insufficiency and explore their potential application as therapeutic targets.

Even so, the findings arrive at a moment of mounting public concern about chemical exposures and fertility. Global prevalence estimates for premature ovarian insufficiency, together with rising attention to declining fertility across many countries, have intensified the search for modifiable risk factors. If a molecular pathway such as the miR-26a-3p and CCND1 axis proves robust in follow-up studies, it could open several doors at once: a biomarker signature for early detection of ovarian stress, a mechanistic test for screening suspected endocrine disruptors, and a target for interventions designed to protect granulosa cell function. The study was supported by the Zhejiang Provincial Basic Public Welfare Research Plan Project and related provincial health research programs, reflecting institutional investment in untangling the environmental roots of reproductive disease. For now, the image that lingers is a deceptively simple one: a ubiquitous plastic additive, a twenty-two-nucleotide RNA fragment, and a single cell cycle protein, locked together in a circuit that may help decide how long a woman’s ovaries keep working.

Subject of Research: MicroRNA-mediated regulation of Cyclin D1 in bisphenol A-associated premature ovarian insufficiency

Article Title: Possible Involvement of miR-26a-3p in Regulating Cyclin D1(CCND1) in the Pathogenesis of Premature Ovarian Insufficiency (POI)

Article References: Du, E., Pan, J., Zhang, L., & Xu, W. (2026). Possible Involvement of miR-26a-3p in Regulating Cyclin D1(CCND1) in the Pathogenesis of Premature Ovarian Insufficiency (POI). Reproductive Sciences. https://doi.org/10.1007/s43032-026-02218-0

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02218-0

Keywords: premature ovarian insufficiency, miR-26a-3p, Cyclin D1, CCND1, bisphenol A, granulosa cells, microRNA, endocrine disruptor, cell cycle, ovarian proliferation, reproductive sciences, female fertility

The compound at the center of the study is zerumbone, a sesquiterpene found in abundance in the rhizomes of Zingiber zerumbet, a plant widely used in traditional medicine across Southeast Asia and parts of India. Zerumbone has attracted scientific attention for years because of reported anti-inflammatory and anticancer properties, but its precise molecular targets have remained incompletely understood. The research team set out to determine whether zerumbone might act on interleukin-10, a signaling molecule with a complicated role in cancer biology. Interleukin-10 is classically described as an anti-inflammatory cytokine, damping down immune responses to protect tissues from damage. Yet in the tumor microenvironment, that same immunosuppressive function can become a liability, allowing cancer cells to evade immune surveillance while simultaneously promoting pathways that support their own proliferation and survival.

To interrogate this hypothesis, the investigators deployed an integrative workflow that has become increasingly common in modern pharmacology: network pharmacology paired with structural biology simulations. Network pharmacology treats a drug not as a single bullet aimed at a single target but as a molecule that perturbs an entire web of interacting genes and proteins. Using the STRING database, which catalogs known and predicted protein-protein interactions, the team mapped the network surrounding interleukin-10 and then applied Gene Ontology and KEGG pathway enrichment analyses to identify the biological processes most strongly associated with that network. The results pointed decisively toward the JAK–STAT signaling pathway, a canonical intracellular relay system through which interleukin-10 exerts its effects on immune homeostasis, inflammation, and cell fate.

The JAK–STAT pathway deserves a brief technical explanation because it is central to the study’s logic. When interleukin-10 binds its receptor on a cell surface, it activates Janus kinases, enzymes that phosphorylate STAT proteins, chiefly STAT3 in the interleukin-10 context. Once activated, STAT3 travels to the nucleus and switches on genes that drive cell cycle progression and block programmed cell death. Two of the most important downstream products are Cyclin D1, which pushes cells through the G1 phase of the cell cycle, and Bcl-xL, a member of the Bcl-2 family that shields cells from apoptosis. In many cancers, including cervical cancer, this axis is chronically activated, effectively locking tumor cells into a state of unchecked division and resistance to cell death. A molecule that disrupts interleukin-10 signaling upstream could, in principle, quiet the entire cascade.

With the pathway identified, the researchers turned to molecular docking, a computational technique that predicts how a small molecule fits into the binding pockets of a protein target. The docking analyses suggested that zerumbone associates stably with a functionally relevant region of interleukin-10, occupying a site that could plausibly interfere with the cytokine’s normal interactions. Docking alone, however, produces a static snapshot, and proteins are anything but static. To address this limitation, the team ran molecular dynamics simulations, which track the motion of every atom in the protein-ligand complex over time. If a docked pose is an artifact, it typically falls apart within nanoseconds of simulation; if it is genuine, the complex remains stable. The simulations supported a stable association between zerumbone and interleukin-10, strengthening the computational case that the interaction is physically meaningful rather than a fleeting coincidence of shape matching.

Computational predictions, no matter how sophisticated, must ultimately face the test of living cells. The researchers therefore moved to laboratory experiments using HeLa cells, a cervical cancer cell line derived from a tumor that has been studied continuously since the 1950s and remains a standard model for this disease. Using enzyme-linked immunosorbent assays to measure cytokine concentrations in the culture medium, the team quantified how zerumbone treatment affected interleukin-10 release. The results were striking and clearly dose-dependent. At a concentration of 1 micromolar, the cells secreted interleukin-10 at approximately 70.81 picograms per milliliter. As the zerumbone concentration rose to 40 micromolar, that figure collapsed to just 6.32 picograms per milliliter, a reduction of roughly ninety percent across the dose range tested.

The suppression of interleukin-10 was accompanied by changes in the downstream markers that the network analysis had predicted. Zerumbone treatment was associated with modulation of Cyclin D1 and Bcl-xL, the proliferative and anti-apoptotic effectors of the JAK–STAT cascade. This concordance between prediction and experiment is the methodological heart of the study. The computational pipeline flagged a pathway; the docking and dynamics studies proposed a physical mechanism; and the cell-based assays then confirmed that treating cells with the compound produced the expected molecular consequences. Taken together, the authors argue, the findings suggest that zerumbone modulates apoptotic and proliferative signaling through the interleukin-10 pathway, producing strong anticancer activity in this model system.

The significance of this work extends beyond a single compound and a single cancer type. Cervical cancer cells are known to manipulate the cytokine environment to their advantage, and interleukin-10 is one of several immunosuppressive signals they deploy. Current immunotherapies, such as immune checkpoint inhibitors, have shown only modest benefit in cervical cancer compared with some other tumor types, which makes the search for alternative ways to relieve immunosuppression clinically relevant. If a small, naturally derived molecule can dampen interleukin-10 production directly in tumor cells, it could complement existing treatments or inspire the design of more potent analogs. The JAK–STAT pathway itself is already a validated drug target, with JAK inhibitors approved for inflammatory diseases and under investigation in oncology, which lends additional plausibility to the therapeutic concept.

At the same time, the researchers and outside observers alike will recognize the distance between a cell culture dish and a patient. HeLa cells are a powerful but simplified model, and the tumor microenvironment in a living body involves many additional cell types, cytokines, and regulatory feedback loops that a two-dimensional culture cannot fully reproduce. Questions about bioavailability, metabolism, toxicity, and appropriate dosing of zerumbone in humans remain open, as do questions about whether the interleukin-10 suppression observed in vitro translates into meaningful antitumor immunity in vivo. The study also involved no new human or animal subjects, so the findings rest entirely on computational and in vitro evidence. These are standard limitations for early-stage natural product research, but they define the road ahead: animal studies and, eventually, carefully designed clinical trials would be needed before zerumbone could be considered a therapeutic candidate.

What the study does deliver is a compelling proof of concept and a demonstration of methodological rigor in a field that sometimes suffers from the opposite. By chaining together network pharmacology, pathway enrichment, molecular docking, molecular dynamics simulation, and quantitative cell-based validation, the team built a coherent chain of evidence linking a traditional medicine compound to a specific, mechanistically understood signaling axis in cervical cancer. The near-total suppression of interleukin-10 release at higher zerumbone concentrations, and the corresponding modulation of Cyclin D1 and Bcl-xL, provide concrete, testable endpoints for future work. As interest in plant-derived therapeutics continues to grow, studies of this kind show how computational tools can sharpen the search, turning centuries of ethnobotanical knowledge into precise molecular hypotheses that modern laboratories can verify, refine, and one day perhaps translate into new options for patients with cervical cancer.

Subject of Research: Zerumbone targeting IL-10–mediated JAK–STAT signaling in cervical cancer

Article Title: Targeting IL-10–mediated JAK–STAT signaling in cervical cancer: integrative network pharmacology, molecular docking, and experimental validation of Zerumbone

Article References: Singh, S. P., Nongalleima, K., Chanu, W. K., Singh, N. I., Singh, T. D., Swapana, N., Singh, T. R., & Singh, C. B. (2026). Targeting IL-10–mediated JAK–STAT signaling in cervical cancer: integrative network pharmacology, molecular docking, and experimental validation of Zerumbone. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05589-8

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05589-8

Keywords: zerumbone, IL-10, JAK-STAT signaling, cervical cancer, HeLa cells, molecular docking, molecular dynamics simulation, network pharmacology, Cyclin D1, Bcl-xL, natural compounds, anticancer research